Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

Results of the Hermine study examining the use of trastuzumab for metastatic breast cancer patients in routine practice, including patients who received trastuzumab treatment beyond progression, are reported. The cardiac safety of trastuzumab in this setting is also reported

Le tamoxifène en situation adjuvante dans le cancer du sein : trente ans d’expérience

Colloque avec actes et comité de lecture. Internationale.International audienceLe tamoxifène a été pendant près de trente ans l’hormonothérapie de référence dans le traitement (adjuvant) du cancer du sein. Le tamoxifène a été le standard défini dans tous les consensus internationaux européens ou américains. Il reste le standard chez la femme non ménopausée. En 30 ans d’essais cliniques, les données sur son mode d’action, sa tolérance, sa toxicité, son efficacité et ses indications se sont accumulées

Facteurs pronostiques de survie des cancers métastatiques du sein

CAEN-BU Médecine pharmacie (141182102) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Les facteurs de risque de rechute locale après traitement conservateur du cancer du sein (étude rétrospective menée au centre François Baclesse)

CAEN-BU Médecine pharmacie (141182102) / SudocSudocFranceF

Rôle de l'irradiation de la chaîne mammaire interne après mastectomie dans le cancer du sein

CAEN-BU Médecine pharmacie (141182102) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Chimiothérapie adjuvante dans le cancer du sein (étude de dose-intensite)

CAEN-BU Médecine pharmacie (141182102) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Influence of CA 15-3 blood level and doubling time on diagnostic performances of 18F-FDG PET in breast cancer patients with occult recurrence

International audienc

Can Sequential Administration Minimise the Cost of High Dose Chemotherapy?: An Economic Assessment in Inflammatory Breast Cancer

Objective: To evaluate the potential cost savings of using sequential high dose chemotherapy (HDC), with granulocyte colony-stimulating factor (filgrastim) and stem cell support, rather than single course administration of HDC with bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT). Perspective: French public hospital perspective. Methods: Direct medical costs of sequential treatment, estimated on the basis of physical quantities of resources consumed by 95 patients with inflammatory breast cancer (IBC) included in a French pilot multicentric trial (PEGASE 02), were compared with those of historical control groups of patients treated with single course HDC, either with BMT (n = 27) or PBSCT (n = 14). Costs were evaluated in 1998 French francs (1 Results: The total cost of sequential HDC was significantly lower than that for single course HDC both with BMT (-29%; Conclusion: According to our results, economic arguments cannot be used against the widespread use of sequential HDC for patients with IBC. However, further economic evaluations based on overall and disease-free survivals alongside a randomised clinical trial are still needed to definitively establish the cost effectiveness of sequential administration of HDC.Antineoplastics, Bone-marrow-transplant, Breast-cancer, Cisplatin, Cost-analysis, Cyclophosphamide, Doxorubicin, Etoposide, Mitoxantrone, Melphalan, Pharmacoeconomics, Fluorouracil, Filgrastim, Granulocyte-colony-stimulating-factors, Stem-cell-transplant